Ignite Creation Date:
2024-05-06 @ 11:16 AM
Last Modification Date:
2024-10-26 @ 12:42 PM
Study NCT ID:
NCT03470311
Status:
COMPLETED
Last Update Posted:
2023-01-20
First Post:
2018-03-01
Brief Title:
Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies
Sponsor:
McMaster University
Organization:
McMaster University
Study Overview
Official Title:
Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In severe prednisone-dependent eosinophilic asthma Benralizumab would suppress airway eosinophilia that is not suppressed by either Mepolizumab or Reslizumab and this would be associated with greater asthma control
Detailed Description:
Benralizumab thus targets eosinophil biology by inhibiting the interleukin IL-5 receptor signalling and inducing apoptosis in cells with an IL-5receptor Hence for patients who remain uncontrolled on anti-IL-5 therapy with detectable eosinophil activity and IL5-Rα cells in the airways the investigators believe would benefit from a strategy that not only reduces eosinophil proliferationrecruitmentmaturation but also depletes cells capable of inducing downstream IL-5 signalling
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None